重组人血管内皮抑制素 (先声药业)(Recombinant Human Endostatin (Simcere)) - 药物靶点：VEGFR_在研适应症：非小细胞肺癌，恶性腹水，恶性胸腔积液_专利_临床

概要

基本信息

药物类型

重组蛋白

别名

Endostar、Endu、rh-endostatin

+ [2]

靶点

VEGFR

作用机制

VEGFR拮抗剂(血管内皮细胞生长因子受体拮抗剂)

治疗领域

肿瘤呼吸系统疾病其他疾病

在研适应症

非小细胞肺癌恶性腹水恶性胸腔积液

非在研适应症

晚期结直肠腺癌晚期肺腺癌晚期非小细胞肺癌+ [5]

原研机构

先聲藥業集團有限公司

在研机构

山东先声生物制药有限公司

非在研机构

江苏先声药业有限公司

最高研发阶段批准上市

首次获批日期

中国 (2005-09-12),

非小细胞肺癌

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

Sequence Code 720094457

关联

98

项与重组人血管内皮抑制素 (先声药业) 相关的临床试验

NCT06618391

/ Not yet recruiting临床2期IIT

Envafolimab and Recombinant Human Endostatin and Recombinant Human Adenovirus Type 5 Intratumor Local Injection Combined With Systemic Therapy in Patients With Advanced NSCLC :a Prospective, Exploratory Phase II Clinical Study Tudy

This study is a prospective, exploratory Phase II clinical study aimed at evaluating the safety and efficacy of Envafolimab and recombinant human endostatin and Recombinant Human Adenovirus Type 5 Intratumor local injection combined with systemic therapy in patients with locally advanced or advanced non-small cell lung cancer(NSCLC).

开始日期2024-10-08

申办/合作机构

河南省肿瘤医院

NCT06617936

/ Recruiting临床2期IIT

Tislelizumab Combined With Recombinant Human Endostatin Injection Plus Chemotherapy in Unresectable Stage III NSCLC: a Prospective, Single-arm, Multicenter Phase II Clinical Study

This is a prospective, single-arm, multicenter, phase II clinical study designed to evaluate the initial efficacy and safety of patients receiving Tislelizumab in combination with recombinant human endostatin injection plus chemotherapy for stage III unresectable non-small cell lung cancer. To evaluate the surgical conversion rate of tirellizumab combined with recombinant human endostatin injection and chemotherapy induction therapy in patients with initially unresectable stage III non-small cell lung cancer.

开始日期2024-08-27

申办/合作机构

上海大众卫生投资有限公司

ChiCTR2400088085

/ Suspended早期临床1期IIT

Efficacy and safety of intra-arterial cisplatin plus anti-angiogenesis inhibitor rh-endostatin (Endostar) combined with systematic chemotherapy in osteosarcoma

开始日期2024-08-20

申办/合作机构-

100 项与重组人血管内皮抑制素 (先声药业) 相关的临床结果

登录后查看更多信息

100 项与重组人血管内皮抑制素 (先声药业) 相关的转化医学

登录后查看更多信息

100 项与重组人血管内皮抑制素 (先声药业) 相关的专利（医药）

登录后查看更多信息

487

项与重组人血管内皮抑制素 (先声药业) 相关的文献（医药）

2024-12-01·HNO

Article

作者: Tribius, Silke ; Gostian, Antoniu-Oreste ; Hecht, Markus ; Schnellhardt, Sören ; Linxweiler, Maximilian

At the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO), several important studies on radiotherapy for head and neck squamous cell carcinoma (HNSCC) were presented. There were two Chinese phase III trials on treatment escalation for locally advanced nasopharyngeal carcinoma: adjuvant immune checkpoint inhibition with camrelizumab after induction chemotherapy and cisplatin-based chemoradiotherapy (RCT) in the DIPPER trial reached the primary endpoint of improved event-free survival (EFS) but did not improve overall survival (OS). Simultaneous and adjuvant administration of the angiogenesis inhibitor endostar in addition to cisplatin-based RCT for locally advanced nasopharyngeal carcinoma led to a significant improvement in progression-free survival (PFS) and OS. Another major focus was on treatment optimization and deintensification for oropharyngeal cancer (OPC): using intensity-modulated proton therapy (IMPT), a phase III trial demonstrated noninferiority in definitive RCT for OPC compared to photon-based intensity-modulated radiotherapy (IMRT). In adjuvant treatment of human papillomavirus-positive (HPV+) OPC, the long-term results of the E3311 phase II study confirmed that individually deintensified radiotherapy is feasible. Lee et al. showed with the results of a phase II study that HPV+ OPC might be treatable with chemoradiotherapy to a total dose of only 30 Gy if no hypoxia is detected in the ¹⁸F‑fluoromisonidazole positron-emission tomography-computed tomography (F-MISO-PET) scan. Both the deintensified treatment of HPV+ OPC as well as additive immune checkpoint and angiogenesis inhibition in chemoradiotherapy of nasopharyngeal carcinoma require further studies before they can be recommended in clinical practice.

2024-12-01·BMJ Open

Thoracic perfusion of antiangiogenic agents combined with chemotherapy for treating malignant pleural effusion in non-small cell lung cancer: a network meta-analysis

Review

作者: Si, Wei ; Jiang, Liming ; Zhu, Xiaohua ; Yu, Yinan ; Cui, Yingying ; Xu, Yan

Objectives:

Different intrathoracic perfusion therapeutic regimens are available for non-small cell lung cancer with malignant pleural effusion (MPE). Antiangiogenic agents are often used to control MPE, and the results are satisfactory. Here, we performed a network meta-analysis to reveal optimal combinations of antiangiogenic agents and chemical agents and assess their effectiveness and safety.

Design:

Systematic review and network meta-analysis.

Data sources:

PubMed/Medline, Embase, Cochrane, Web of Science, Wanfang, VIP Database and Chinese National Knowledge Infrastructure were searched from inception to May 2023. Eligible studies were randomised controlled trials that reported on curative effect of MPE.

Data extraction and synthesis:

The Cochrane Collaboration tool was used to assess risk of bias. The consistency was evaluated by examining the agreement between direct and indirect effects. Network meta-analysis was performed and the ranking probabilities of being at each possible rank for each intervention were estimated. Comparison-adjusted funnel plots were obtained to assess publication bias.

Results:

A total of 46 studies were included in the analysis. Among them, we included a total of seven interventions. A total of 3026 patients participated in this analysis. According to the results of the network meta-analysis, some antiangiogenic agents combined with chemotherapy regimens improved objective response rate (ORR) and disease control rate (DCR) and quality of life (QOL). The rank probabilities suggested that in terms of ORR, DCR and QOL, Endostar plus lobaplatin was the first-ranked intervention.

Conclusion:

Administration of antiangiogenic agents plus chemical agents significantly improved the clinical response and QOL. In addition, Endostar plus lobaplatin was the most effective combination.

PROSPERO registration number:

CRD42021284786.

2024-08-01·European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery

Anti-angiogenesis agents plus chemoradiotherapy for locally advanced nasopharyngeal cancer: a systematic review and meta-analysis

Review

作者: Xin, Yong ; Lou, Yufei ; Zhu, Youqi ; Sun, Xueqing ; Lu, Xinyu ; Guo, Yilong ; Wang, Bo ; Yu, Dehong

PURPOSE:

To evaluate literature evidences about the efficacy and safety of anti-angiogenesis agents plus chemoradiotherapy versus chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma.

METHODS:

The relevant literature was systematically searched from the date of establishment to April 2023 in PubMed, Embase, Web of Science, The Cochrane Library, Chinese National Knowledge Infrastructure, Chinese Biological Medicine, Wanfang and VIP database. Search terms included: Nasopharyngeal Neoplasms, Angiogenesis inhibitors, Endostar, Anlotinib, Apatinib, Bevacizumab, Sunitinib, Pazopanib, Chemoradiotherapy. The literature was strictly screened according to the inclusion and exclusion criteria, and 8 eligible studies were finally included in our meta-analysis (4 randomized controlled trials and 4 retrospective studies).

RESULTS:

A total of 642 patients were included, with 316 in the anti-angiogenesis agents plus chemoradiotherapy group and 326 in the chemoradiotherapy group. The results of our meta-analysis showed that compared with chemoradiotherapy group, the complete response rate (RR = 1.35, 95% CI 1.05-1.74, P = 0.02), objective response rate (RR = 1.26, 95% CI 1.12-1.43, P = 0.0002) in the anti-angiogenesis agents plus chemoradiotherapy group were significantly improved. In terms of safety, there was a higher incidence of cardiac arrhythmia (RR = 3.63, 95% CI 1.16-11.37, P = 0.03) and hypertension (RR = 1.85, 95% CI 1.04-3.27, P = 0.004) in the anti-angiogenesis agents plus chemoradiotherapy group, while no statistically significant differences were reported in other adverse reactions (all P > 0.05).

CONCLUSION:

Compared with chemoradiotherapy, anti-angiogenesis agents plus chemoradiotherapy could bring more benefits in terms of short-term efficacy, particularly by notably improving both complete response rate and objective response rate, and overall adverse reactions were acceptable. Anti-angiogenesis agents plus chemoradiotherapy may provide a promising direction for the treatment of locally advanced nasopharyngeal carcinoma.

SYSTEMATIC REVIEW REGISTRATION:

https://inplasy.com/inplasy-2023-8-0076/ , registration number INPLASY202380076.

57

项与重组人血管内皮抑制素 (先声药业) 相关的新闻（医药）

2025-01-14

·艾伯维abbvie

艾伯维宣布与先声再明合作开发治疗多发性骨髓瘤的新型三特异性抗体候选药物

1月 13 日，艾伯维与先声药业集团有限公司子公司先声再明宣布，双方就在研候选药物SIM0500达成许可选择协议。SIM0500目前正在中美两国开展针对复发或难治性多发性骨髓瘤(MM)的临床1期研究。 SIM0500是一种靶向GPRC5D、BCMA和 CD3的人源化三特异性抗体，由先声再明使用其 T 细胞衔接器多特异性抗体技术平台独立开发。该分子结合了低亲和力而高靶向激活的CD3抗体，以及抗G蛋白偶联受体C家族5组成员D（GPRC5D）和抗B细胞成熟抗原（BCMA）的两种抗肿瘤相关抗体。SIM0500通过多种抗肿瘤机制，表现出了针对MM细胞的强大T细胞毒性效应。 Mariana Cota Stirner博士艾伯维副总裁、血液肿瘤治疗领域负责人作为血液肿瘤领域的领导者，艾伯维致力于通过不懈的研发和合作，推进针对多发性骨髓瘤等复杂肿瘤的创新疗法。我们期待与先声再明合作，推进这种新型的三特异性抗体的研发。它有可能帮助解决多发性骨髓瘤患者尚未满足的重大临床需求。唐仁宏博士先声再明首席执行官 SIM0500是通过先声再明专有的T细胞接触器平台开发的。我们很高兴能与艾伯维合作开发这种新的候选药物，并期待共同推进 SIM0500的临床开发进程。先声再明将获得艾伯维的首付款，以及最高10.55亿美金的选择性权益付款和里程碑付款。先声再明将额外获得基于该产品在大中华区以外地区净销售额的分级特许权使用费。艾伯维有权获得大中华区净销售额的分级特许权使用费。关于艾伯维肿瘤学领域在艾伯维，我们致力于改变难以治疗的肿瘤患者的护理标准。我们正在推进针对血液肿瘤和实体肿瘤中各种肿瘤类型的动态研究疗法产品线。我们正在专注于开发能够阻碍肿瘤细胞繁殖或消除肿瘤细胞的靶向药物。我们通过各种靶向治疗模式和生物学干预来实现这一目标，包括小分子疗法、抗体药物偶联物（ADC）、基于免疫肿瘤学的疗法、多特异性抗体和原位CAR-T平台。我们敬业且经验丰富的团队与创新合作伙伴联手，加快潜在突破性药物的交付。如今，我们广泛的肿瘤学产品组合包括针对各种血液和实体肿瘤的已获批准和在研的治疗方法。我们正在针对世界上一些最广泛和最令人衰弱的肿瘤的多项临床试验中评估20多种在研药物。在我们努力对人们的生活产生显著影响的同时，我们致力于探索解决方案，帮助患者获得我们的抗肿瘤药物。欲了解更多信息，请访问 http://www.abbvie.com/oncology。关于先声再明先声再明是先声药业集团旗下专注于抗肿瘤创新药研发、生产和商业化的生物医药公司，2023年起独立运营，致力于以突破性治疗手段, 解决中国乃至全球肿瘤领域巨大的未满足临床需求。再明着力打造高价值创新管线，已上市产品组合包含科赛拉®、恩维达®、恩度®、恩立妥®4款创新药。再明与全球合作伙伴的协同创新，为临床提供更有效的治疗手段，让更多肿瘤患者再现生机与光明。上下滑动查看更多信息艾伯维前瞻性陈述本新闻稿中的某些陈述可能为前瞻性陈述。“相信”、“期望”、“预期”、“计划”和类似表达通常被视为前瞻性陈述。艾伯维提醒，这些前瞻性陈述存在风险和不确定性，可能导致实际结果与前瞻性陈述中指出的结果有重大差异。这些风险和不确定性包括但不限于：知识产权的挑战；来自其他产品的竞争；研发过程中固有的困难；不利的诉讼和政府行为；适用于我们行业的法律法规的变化。关于可能影响艾伯维运营的经济、竞争、政府、技术和其他因素的额外信息，请参见艾伯维提交给美国证券交易委员会的2023年度报告的10-K表格的第1A项“风险因素”，以及随后更新的季度报告的10-Q表格。除非法律要求，艾伯维不承担因后续事件或发展而公开发布对前瞻性陈述的任何修订的义务。

免疫疗法细胞疗法抗体药物偶联物临床1期引进/卖出

2025-01-13

·PRNewswire

Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma

SHANGHAI and NORTH CHICAGO, Ill., Jan. 13, 2025 /PRNewswire/ -- Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) and AbbVie Inc. (NYSE: ABBV) today announced an option to license agreement to develop SIM0500, an investigational new drug candidate. SIM0500 is currently in Phase 1 clinical trials in patients with relapsed or refractory multiple myeloma (MM), in both China and the U.S. Continue Reading Cooperation of Simcere Zaiming and Abbvie SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3, developed independently by Simcere Zaiming using their T-cell engager polyspecific antibody technology platform. This molecule features a low affinity/high target-activating CD3 engaging arm and binding sites for the two tumor antigens: G-Protein-coupled receptor class 5 member D (GPRC5D) and B-cell maturation antigen (BCMA). SIM0500 has shown strong T cell cytotoxicity against multiple myeloma (MM) cells by leveraging a combination of various antitumor effects. "As a leader in hematologic malignancies, AbbVie is committed to advancing innovative treatments for complex cancers like multiple myeloma through our relentless R&D efforts and collaborations," said Mariana Cota Stirner, M.D., Ph.D., vice president, therapeutic area head for hematology, AbbVie. "We look forward to partnering with Simcere Zaiming, to advance this novel trispecific antibody, which has the potential to help address significant unmet medical needs for people living with multiple myeloma" "SIM0500 is developed via Simcere Zaiming's proprietary T-cell engager platform," said Renhong Tang, PhD, CEO of Simcere Zaiming. "We are excited to partner with AbbVie on this novel drug candidate and look forward to working together to advance the clinical development of SIM0500. " Simcere Zaiming will receive an upfront payment from AbbVie and is eligible to receive option fees and milestone payments of up to $1.055B, as well as tiered royalties on net sales outside of the Greater China territory. AbbVie is eligible to receive tiered royalties on net sales in the Greater China territory About AbbVie in Oncology At AbbVie, we are committed to transforming standards of care for patients living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various, targeted treatment modalities and biology interventions, including small molecule therapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based therapeutics, multispecific antibody and in situ CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines. Today, our expansive oncology portfolio comprises approved and investigational treatments for a wide range of blood and solid tumors. We are evaluating more than 20 investigational medicines in multiple clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit . About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. AbbVie strives to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in AbbVie's Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at . Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube. About Simcere Zaiming Simcere Zaiming is an oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Limited (HKEX: 2096, "Simcere"). Founded in 2023, Simcere Zaiming dedicated to developing groundbreaking therapies to meet the unmet clinical needs of cancer patients globally. With a robust and innovative R&D pipeline featuring distinct clinical assets, Simcere Zaiming has successfully launched several innovative products in China, including COSELA®, Enweida®, Endostar®, and Enlituo®. The company is determined to deliver potentially transformative treatment options to cancer patients worldwide through its internal R&D, manufacturing, and commercialization capabilities, complemented by strategic collaborations with leading partners. SOURCE Simcere Zaiming WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

引进/卖出临床1期抗体药物偶联物

2025-01-13

·先声药业

先声再明与艾伯维就多发性骨髓瘤三抗候选创新药开发达成合作

中国上海与美国北芝加哥，2025年1月13日，先声药业集团（2096.HK）旗下抗肿瘤创新药公司先声再明与全球生物制药公司艾伯维（AbbVie）今日宣布，双方已就先声再明的在研候选药物SIM0500达成许可选择协议。SIM0500目前正在中美两国开展针对复发或难治性多发性骨髓瘤（MM）的临床I期研究。 SIM0500是一款人源化GPRC5D-BCMA-CD3三特异性抗体，由先声再明通过其专有的T细胞衔接器多特异性抗体技术平台开发。该分子结合了低亲和力而高靶向激活的CD3抗体，以及抗G蛋白偶联受体C家族5组成员D（GPRC5D）和抗B细胞成熟抗原（BCMA）的两种抗肿瘤相关抗体。SIM0500通过多种抗肿瘤机制，表现出了针对MM细胞的强大T细胞毒性效应。艾伯维副总裁兼血液学治疗领域负责人Mariana Cota Stirner博士表示：“作为血液肿瘤领域的领先企业，艾伯维致力于通过研发与合作的不懈努力，开发针对多发性骨髓瘤等复杂癌症的创新疗法。我们期待与先声再明携手，推进这种新型三特异性抗体的研发。它有可能为多发性骨髓瘤患者带来显著的改善，满足他们尚未满足的临床需求。” 先声再明CEO唐任宏博士表示：“SIM0500是先声再明T细胞衔接器技术平台的研发成果。我们非常高兴能与艾伯维就这款创新候选药物达成合作，期待双方协同配合，推进该药物的临床开发进程。” 根据该协议条款，先声再明将从艾伯维收取首付款，以及最高10.55亿美金的选择性权益付款和里程碑付款。先声再明将额外获得基于该产品在大中华区以外地区净销售额的分级特许权使用费。艾伯维有权就大中华地区净销售额收取分级特许权使用费。先声再明是先声药业集团旗下专注于抗肿瘤创新药研发、生产和商业化的生物医药公司，2023年起独立运营，致力于以突破性治疗手段, 解决中国乃至全球肿瘤领域巨大的未满足临床需求。再明着力打造高价值创新管线，已上市产品组合包含科赛拉®、恩维达®、恩度®、恩立妥®4款创新药。再明与全球合作伙伴的协同创新，为临床提供更有效的治疗手段，让更多肿瘤患者再现生机与光明。媒体联络：pr@zaiming.com 艾伯维致力于改革多种难治性肿瘤的标准治疗。公司不断丰富的研发管线涵盖多种类型的血液肿瘤和实体瘤。艾伯维利用各种靶向治疗技术和生物学手段，包括小分子药物、抗体偶联药物（ADC）、肿瘤免疫药物，多特异抗体与原位CAR-T平台，聚焦于开发能够阻止肿瘤细胞复制或消除肿瘤的靶向治疗药物。艾伯维的专业团队凭借丰富的经验，与创新合作伙伴携手加速推动突破性药物的开发。目前艾伯维已建立了丰富的抗肿瘤产品组合，包括针对血液肿瘤和实体瘤的多种已获批药物以及在研项目。公司正针对全球最广泛、最严重的癌症开展多项临床试验，对20余种在研药物进行评估。在为人们带来深远影响的同时，艾伯维也致力于探索帮助患者获得癌症治疗的解决方案。http://www.abbvie.com/oncology 艾伯维的使命是探索并提供创新药物及解决方案，旨在攻克当下严峻的健康问题及应对未来的医疗挑战。艾伯维力求在免疫学、肿瘤学、神经科学、眼部护理以及AbbVie Allergan Aesthetics产品组合等多个关键治疗领域为人们的生活带来深远影响。更多信息请登录www.abbvie.com，也可在LinkedIn, Facebook, Instagram, X （曾用名Twitter), YouTube等网站@abbvie进行关注。编辑 | 李逸玲审校 | 陈瑶张静审核 | 高兴元孙建成

免疫疗法抗体药物偶联物细胞疗法临床1期引进/卖出

100 项与重组人血管内皮抑制素 (先声药业) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	L01	DB06423

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
非小细胞肺癌	中国	山东先声生物制药有限公司	2005-09-12

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
恶性腹水	临床3期	中国	山东先声生物制药有限公司	2021-07-21
恶性胸腔积液	临床3期	中国	山东先声生物制药有限公司	2021-07-21
局部晚期非小细胞肺癌	临床3期	中国	江苏先声药业有限公司	2018-08-01
晚期结直肠腺癌	临床3期	中国	江苏先声药业有限公司	2018-07-01
晚期肺腺癌	临床2期	中国	江苏先声药业有限公司	2012-03-01
脑转移瘤	临床2期	中国	江苏先声药业有限公司	2011-06-01
T细胞淋巴瘤	临床2期	中国	江苏先声药业有限公司	2011-06-01
食管癌	临床2期	中国	江苏先声药业有限公司	2011-05-01
晚期非小细胞肺癌	临床1期	中国	山东先声生物制药有限公司	2021-07-15
转移性非小细胞肺癌	临床1期	中国	山东先声生物制药有限公司	2021-07-15

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


WCLC2024 人工标引	临床2期	非小细胞肺癌一线 driver gene-negative	29	EnvafolimabRh-endostatin	遞鬱廠鏇窪顧壓廠繭繭(襯壓窪觸餘衊範鏇願壓) = 鏇壓鏇餘憲製構鹹糧蓋鹽繭憲製膚積網築糧獵 (構衊艱鏇觸鑰鹽遞齋獵, 76.8 ~ 109.4) 更多	积极	2024-09-09
NCT05574998 (Pubmed)	临床2期	晚期非小细胞肺癌 serum carcinoembryonic antigen (CEA)	48	rh-endostatin + platinum with pemetrexed	襯憲製糧觸積範糧鹽鏇(廠憲鏇範鬱壓獵鏇壓壓) = 構鏇築壓鏇觸廠遞蓋鏇網夢醖醖衊簾蓋襯鹹糧 (鹹簾獵襯築夢淵醖鹹蓋, 3.8 ~ 9.1) 更多	积极	2024-06-01
				rh-endostatin + platinum with paclitaxel	襯憲製糧觸積範糧鹽鏇(廠憲鏇範鬱壓獵鏇壓壓) = 網顧憲齋遞膚醖鹹夢衊網夢醖醖衊簾蓋襯鹹糧 (鹹簾獵襯築夢淵醖鹹蓋, 3.8 ~ 9.1) 更多
NCT02907710 (phase III, ASCO2024) 人工标引	临床3期	晚期鼻咽癌	300	Endostar plus CCRT	鏇築鑰膚襯窪齋築鑰積(淵繭構醖鏇衊築膚鬱觸) = 淵遞淵獵夢齋壓夢膚範艱鑰鏇鏇鹹遞範鹽廠鬱 (壓齋鹽製廠構鏇觸糧構 ) 更多	积极	2024-05-24
				CCRT alone	鏇築鑰膚襯窪齋築鑰積(淵繭構醖鏇衊築膚鬱觸) = 鏇構製製鏇選範壓觸鑰艱鑰鏇鏇鹹遞範鹽廠鬱 (壓齋鹽製廠構鏇觸糧構 ) 更多
ESMO_ASIA2023	临床2期	局部晚期食管鳞状细胞癌	90	Endostar plus concurrent chemoradiotherapy (CCRT)	簾憲廠繭鏇蓋鹽簾夢窪(製繭顧餘獵築積鬱鑰鹹) = 糧膚範鹹網糧鹽廠壓襯齋淵製繭淵廠膚範鏇積 (簾衊鹽齋築餘網鬱鹹壓 ) 更多	积极	2023-12-02
				Concurrent chemoradiotherapy (CCRT)	齋蓋鹹鹹鏇夢遞齋膚簾(艱遞遞廠廠網壓壓壓窪) = 構廠艱簾窪構鹽鹽糧蓋襯積鏇襯鹹糧繭鹽壓獵 (糧構淵艱遞憲構築鹽餘 ) 更多
ESMO 12023 \| ESMO 22023 人工标引	临床2期	局部晚期食管鳞状细胞癌	92	Endostar+concurrent chemoradiotherapy	膚積鹹衊願網選淵範餘(齋衊窪餘窪糧範簾糧繭) = 構構鹽膚糧窪願淵窪簾鬱範醖網膚鹽築遞鹽廠 (膚鹹艱鏇積蓋憲築選醖 ) 更多	积极	2023-10-23
				Concurrent chemoradiotherapy	膚積鹹衊願網選淵範餘(齋衊窪餘窪糧範簾糧繭) = 襯蓋鬱齋壓築願鏇顧膚鬱範醖網膚鹽築遞鹽廠 (膚鹹艱鏇積蓋憲築選醖 ) 更多
ESMO_GCC2023	N/A	局部晚期宫颈癌	41	Endostar combined with chemoradiotherapy	醖壓齋鬱鹽遞壓鏇觸製(繭淵範製憲襯鏇艱構糧) = 憲繭構艱餘製構願網獵獵醖鹽範糧選鬱築蓋遞 (製鹹淵選憲築鏇憲艱壓 ) 更多	-	2023-02-23
				Chemoradiotherapy	醖壓齋鬱鹽遞壓鏇觸製(繭淵範製憲襯鏇艱構糧) = 夢範窪繭衊餘構膚壓築獵醖鹽範糧選鬱築蓋遞 (製鹹淵選憲築鏇憲艱壓 ) 更多
CSCO2022	N/A	-	815	对照治疗组	遞餘獵範鹽膚鏇壓憲窪(艱糧襯廠鏇範觸願鏇艱) = 齋鹽齋襯製鹽鑰憲襯齋廠廠簾衊艱鑰壓觸夢鬱 (夢窪鏇夢膚製觸餘夢願 ) 更多	积极	2022-09-21
				恩度治疗组	遞餘獵範鹽膚鏇壓憲窪(艱糧襯廠鏇範觸願鏇艱) = 鏇積蓋膚鏇餘獵憲範選廠廠簾衊艱鑰壓觸夢鬱 (夢窪鏇夢膚製觸餘夢願 ) 更多
CSCO2022	N/A	肺癌 \| 恶性胸腔积液	78	顺铂	繭獵範糧鬱鹽壓顧淵願(淵鏇淵餘蓋積壓築願鬱) = 鏇淵膚廠餘鏇繭顧鬱簾顧範顧憲膚獵積鑰選鹹 (網範糧願簾憲襯襯築餘 ) 更多	-	2022-09-21
CSCO2022	N/A	晚期鳞状细胞肺癌	19	重组人血管内皮抑制素联合阿法替尼及替吉奥	鹹襯餘顧鏇齋艱構襯遞(鹽選醖網鹽範鑰齋願淵) = 没有与治疗相关的死亡报告窪鑰遞積窪壓選顧淵鏇 (顧簾鏇鹽鑰餘繭鬱淵願 ) 更多	-	2022-09-21
WCLC2022	N/A	晚期非小细胞肺癌	27	Endostar + Camrelizumab + Chemotherapy	衊夢網構鏇壓範憲淵餘(獵遞鹽壓壓遞構廠壓遞) = 醖鏇壓鏇鏇簾糧膚網鏇獵觸製鏇襯範遞憲廠選 (積艱鑰壓構積壓簾顧繭 ) 更多	-	2022-08-06